PK/PD of repurposed Covid-19 drugs
Table 1 summarizes the observed data of pharmacokinetics and pharmacodynamics properties of repurposed COVID-19 drugs. The half-maximal inhibitory concentration (IC50) parameters obtained were treated as unbound IC50, as the experimental conditions utilize serum free conditions for COVID-19 drugs and this hypothesis was recently supported by Fan et al [26]. However, the in vivo plasma and lung tissue concentrations were corrected using in silico predicted tissue protein binding and measured plasma protein binding. The preclinical rat partition co-efficient (Kp) values for lung tissue are compared with human predicted Kp values as listed in Supplementary Table 2 .